Darolutamide Increases Survival in Metastatic Hormone-Sensitive Prostate Cancer
BREAKING NEWS 2022 New research suggests that adding darolutamide to androgen deprivation therapy (ADT) and docetaxel improves overall survival for patients with metastatic hormone-sensitive prostate cancer (mHSPC), compared with ADT plus docetaxel alone. In addition, darolutamide significantly delayed the development…